Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are : to assess the safety and tolerability, to
determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to
determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as Ociperlimab) in
combination with tislelizumab in participants with advanced solid tumors in phase 1.
Primary objective of Phase 1b is to assess overall response rate (ORR) determined by
Investigator per RECIST v1.1 for patients in each dose- expansion